The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 175)
Research Grant, 2018
In the past, we demonstrated that using drugs to deactivate Rho-associated protein kinase (ROCK), a protein regulating shape and movement of cells, can protect dopamine-producing brain cells from damage caused by alpha-synuclein, a sticky protein that clumps in the brains of people with Parkinson's disease (PD). However, the optimal drug for ROCK deactivation in PD has not yet bee...
Target Advancement Program, 2018
Lysosomes -- tiny bubbles inside the cell responsible for disposing of its waste -- don't work as they should in brain cells of people with Parkinson's disease (PD). Lysosomes are filled with various substances, one of which is ceramide. Ceramide metabolism --production and breakdown -- in lysosomes is controlled by four genes (GBA, GALC, SMPD1 and ASAH1), changes (mutations) in w...
Researchers: Benoît Vanderperre, PhD
Therapeutic Pipeline Program, 2018
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). Duplication or triplication of SNCA, a gene responsible for the production of alpha-synuclein, leads to inherited PD. Additional copies of SNCA produce excess of alpha-synuclein, promoting neurodegeneration and increasing the severity of Parkinson's symptoms. We propose to limit ...
Researchers: Jack T. Rogers, PhD
Research Grant, 2017
Parkinson's disease (PD) is characterized by impairment of motor control as a result from extensive neuron death. The primary mechanism responsible for the progressive neuronal loss in PD remains unknown; however, clues have been obtained from families who have a genetic form of PD that is accompanied by a mutation (change in genetic material, or DNA) in an important protein called...
Researchers: Claudio Hetz Flores, PhD
Research Grant, 2017
Promising Outcomes of Original Grant:
Funding from The Michael J. Fox Foundation (MJFF) has facilitated the rapid screening of over 370,000 compounds of chemicals that prevent alpha-synuclein (protein that clumps in the brains of those with Parkinson's) accumulation. At the end of the original grant period, we identified three chemical compounds that could specifically reduce alpha-synuclein accumu...